Suppr超能文献

人血浆中氨基末端脑利钠肽前体的区域性清除。

Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma.

机构信息

Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand.

出版信息

Eur J Heart Fail. 2009 Sep;11(9):832-9. doi: 10.1093/eurjhf/hfp099. Epub 2009 Jul 15.

Abstract

AIMS

Mechanisms for clearance of circulating amino-terminal pro-brain natriuretic peptide (NT-proBNP) remain poorly understood and are relevant to the clinical utility of NT-proBNP as a diagnostic and prognostic biomarker in cardiovascular disorders. We sought to determine site(s) of production and clearance of plasma NT-proBNP in the human circulation.

METHODS AND RESULTS

In 120 subjects undergoing clinically indicated cardiac catheterization, blood samples were collected from arterial and multiple venous sites to measure transorgan gradients of plasma NT-proBNP. Clearance of plasma NT-proBNP occurred across kidney, liver, musculoskeletal, and head and neck tissues. Proportions of calculated total body NT-proBNP clearance were 55-65% across the kidney, 20-25% across the liver, 10-15% across musculoskeletal tissue, and 5-10% across the head and neck. Renal fractional extraction of NT-proBNP was unrelated to estimated glomerular filtration rate. Transorgan gradients, reflecting both renal and extra-renal NT-proBNP degradation, were correlated across multiple clearance sites within an individual.

CONCLUSION

Plasma NT-proBNP is cleared by multiple tissues in the human circulation with approximately 55-65% of total clearance occurring in renal tissue. These data provide the first evidence for extra-glomerular clearance of NT-proBNP and suggest a common multisite clearance mechanism subject to generalized regulation. Renal NT-proBNP extraction was sustained in the face of even moderate levels of kidney dysfunction.

摘要

目的

循环中氨基末端脑利钠肽前体(NT-proBNP)的清除机制仍不清楚,这与 NT-proBNP 作为心血管疾病诊断和预后生物标志物的临床应用有关。我们试图确定人循环中血浆 NT-proBNP 的产生和清除部位。

方法和结果

在 120 名接受临床指征性心导管检查的受试者中,从动脉和多个静脉部位采集血液样本,以测量血浆 NT-proBNP 的跨器官浓度梯度。血浆 NT-proBNP 的清除发生在肾脏、肝脏、肌肉骨骼和头颈部组织。计算得出的全身 NT-proBNP 清除率的比例分别为肾脏 55-65%、肝脏 20-25%、肌肉骨骼组织 10-15%和头颈部 5-10%。NT-proBNP 的肾分馏提取与估计肾小球滤过率无关。反映肾内和肾外 NT-proBNP 降解的跨器官浓度梯度在个体内的多个清除部位之间相关。

结论

人循环中的血浆 NT-proBNP 被多个组织清除,其中约 55-65%的总清除率发生在肾脏组织中。这些数据首次提供了 NT-proBNP 肾小球外清除的证据,并表明存在一种普遍受调节的多部位清除机制。即使在中度肾功能障碍的情况下,肾脏对 NT-proBNP 的提取也能持续进行。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验